Skip to main content
. 2015 Aug 10;12(1-2):119–133. doi: 10.1900/RDS.2015.12.119

Figure 2. Key elements in the management of diabetic nephropathy with established and potential novel therapeutic agents.

Figure 2

Specific classes of oral hypoglycemic and hypolipidemic agents are associated with renoprotective effects. RAS blockade remains the mainstay of treatment. Novel agents that target different pathophysiologic pathways in diabetic nephropathy are being investigated.